C.F.R. homeSearch C.F.R.
C.F.R.Title 42Chapter IV—Centers for Medicare & Medicaid Services, Department of Health and Human ServicesSubchapter C—Medical Assistance ProgramsPart 447—Payments for ServicesSubpart I—Payment for Drugs

42 C.F.R. § 447.514 (2026)

Upper limits for multiple source drugs

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 6 IN 5Y cited 2009–2025 8citing cases
At a glance

Courts have cited this section in 8 opinions since 2009, 6 of them in the last five years.

(a) Establishment and issuance of a listing. (1) CMS will establish and issue listings that identify and set upper limits for multiple source drugs available for purchase by retail community pharmacies on a nationwide basis that FDA has rated at least three drug products as pharmaceutically and therapeutically equivalent in the “Approved Drug Products with Therapeutic Equivalence Evaluations” which is available at http://www.accessdata.fda.gov/scripts/cder/ob/. Only pharmaceutically and therapeutically equivalent formulations will be used to determine such limit, and such limit will only be applied to those equivalent drug products.

(2) CMS publishes the list of multiple source drugs for which upper limits have been established and any revisions to the list in Medicaid Program issuances.

(b) Specific upper limits. (1) The agency's payments for multiple source drugs identified and listed periodically by CMS in Medicaid Program issuances must not exceed, in the aggregate, prior to the application of any federal or state drug rebate considerations, payment levels determined by applying for each pharmaceutically and therapeutically equivalent multiple source drug product, a professional dispensing fee established by the state agency plus an amount established by CMS that is equal to 175 percent of the weighted average of the most recently reported monthly AMPs for such multiple source drugs, using manufacturer submitted utilization data for each multiple source drug for which a Federal upper limit (FUL) is established.

(2) Exception. If the amount established by CMS in paragraph (b)(1) of this section for a pharmaceutically and therapeutically equivalent multiple source drug product is lower than the average retail community pharmacies' acquisition cost for such drug product, as determined by the most current national survey of such costs, CMS will use a percent of the weighted average of the most recently reported monthly AMPs that equals the most current average acquisition costs paid by retail community pharmacies as determined by such survey.

(c) Ensuring a drug is for sale nationally. To assure that a multiple source drug is for sale nationally, CMS will consider the following additional criteria:

(1) The AMP of a terminated NDC will not be used to set the Federal upper limit (FUL) beginning with the first day of the month after the termination date reported by the manufacturer to CMS.

(2) The monthly AMP units data will be used to calculate the weighted average of monthly AMPs for all multiple source drugs to establish the FUL.

(d) The FUL will be applied as an aggregate upper limit.

The 8 cases that cite 42 C.F.R. § 447.514 most heavily, weighted by court and treatment. RelevanceNewestTreatment
cites § 447.514 1×cited by 8 cases
Where it cites § 447.514
“514” (emphasis added)). The Medicaid regulations also direct CMS to set the FUL by calculating “250 percent of the AMP [Average Manufacturer Price] .”
2
NO FLAGRonald Streck v. Eli Lilly & Co., No. 24-1884 (7th Cir. Sept. 11, 2025).
cites § 447.514 1×cited by 0 cases
Where it cites § 447.514
“§1396r-8(e)(4)–(5); 42 C.F.R. §447.514 (2016). Streck’s argument that monthly AMPs, which are completely irrelevant to Lilly’s MDRP obligations to the government, could form the basis of FCA liability was obvi- ously a non-starter from the get-go.”
3
NO FLAGRonald Streck v. Eli Lilly & Co., No. 24-1352 (7th Cir. Sept. 11, 2025).
cites § 447.514 1×cited by 0 cases
Where it cites § 447.514
“§1396r-8(e)(4)–(5); 42 C.F.R. §447.514 (2016). Streck’s argument that monthly AMPs, which are completely irrelevant to Lilly’s MDRP obligations to the government, could form the basis of FCA liability was obvi- ously a non-starter from the get-go.”
4
NO FLAGRonald Streck v. Eli Lilly & Co., No. 23-3035 (7th Cir. Sept. 11, 2025).
cites § 447.514 1×cited by 0 cases
Where it cites § 447.514
“§1396r-8(e)(4)–(5); 42 C.F.R. §447.514 (2016). Streck’s argument that monthly AMPs, which are completely irrelevant to Lilly’s MDRP obligations to the government, could form the basis of FCA liability was obvi- ously a non-starter from the get-go.”
5
NO FLAGRonald J. Streck v. Eli Lilly & Co., No. 23-2958 (7th Cir. Sept. 11, 2025).
cites § 447.514 1×cited by 0 cases
Where it cites § 447.514
“§1396r-8(e)(4)–(5); 42 C.F.R. §447.514 (2016). Streck’s argument that monthly AMPs, which are completely irrelevant to Lilly’s MDRP obligations to the government, could form the basis of FCA liability was obvi- ously a non-starter from the get-go.”
6
NO FLAGRonald J. Streck v. Eli Lilly & Co., No. 23-2216 (7th Cir. Sept. 11, 2025).
cites § 447.514 1×cited by 0 cases
Where it cites § 447.514
“§1396r-8(e)(4)–(5); 42 C.F.R. §447.514 (2016). Streck’s argument that monthly AMPs, which are completely irrelevant to Lilly’s MDRP obligations to the government, could form the basis of FCA liability was obvi- ously a non-starter from the get-go.”
7
NO FLAGRonald J. Streck v. Eli Lilly & Co., No. 23-2134 (7th Cir. Sept. 11, 2025).
cites § 447.514 1×cited by 0 cases
Where it cites § 447.514
“§1396r-8(e)(4)–(5); 42 C.F.R. §447.514 (2016). Streck’s argument that monthly AMPs, which are completely irrelevant to Lilly’s MDRP obligations to the government, could form the basis of FCA liability was obvi- ously a non-starter from the get-go.”
8
GREENIA Dept. of Human Servs. v. Centers for Medicare, No. 08-3284 (8th Cir. Aug. 19, 2009).
cites § 447.514 1×cited by 0 cases
Summary
No passage or summary on file for this case yet.

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
200920172025

One bar per year. Tallest: 6 cases in 2025. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
7th Cir.68th Cir.2
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com